Pregnancy and fertility

The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.

Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.

The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Pregnancy and fertility. The original article is from hmpgloballearningnetwork.com.

Pregnant people with IBD rely on coordinated care across gastroenterology and obstetrics.

A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...

Many reproductive-aged women with IBD and other autoimmune conditions may not have documented claims for prescription or permanent contraception, including women taking medications with potential fetal risks. That gap...

Mothers with chronic diseases such as MS and IBD appear to have higher rates of peripartum mental illness requiring care across serial pregnancies, so awareness and monitoring during and between pregnancies may be...

People with IBD are at higher risk for shingles largely because of immunosuppressive treatments; an effective vaccine (RZV) is recommended by major societies but is underused in some places.

People with IBD often worry whether their disease affects fertility or embryo health. This study directly looks at embryo chromosomal normality during IVF and found similar euploidy rates in patients with and without...

Pregnant people with IBD or other autoimmune diseases often face tough choices about continuing biologics or JAK inhibitors. CARE-HP aims to produce broader, disease-specific evidence to help patients and clinicians...

People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...

This FDA drug-label update describes approved uses and safety warnings for tofacitinib, a JAK inhibitor used in immune-mediated diseases including ulcerative colitis. The boxed warnings highlight serious infection and...

This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to...

This label update confirms current FDA prescribing information for sulfasalazine delayed‑release tablets, which many people with ulcerative colitis may be prescribed for induction and maintenance of remission.

This gives families and clinicians a non‑TNF biologic option on‑label for children aged 2+ with moderate‑to‑severe ulcerative colitis, which can change insurance conversations and expand treatment choices for kids who...

Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...

Prednisone is commonly used short-term in IBD flares; an FDA label update clarifies approved uses and dosing considerations that affect how clinicians prescribe it and how patients should take and stop the drug.

The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.

This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...

This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...

This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...

People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...

The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...

Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....

Keeping IBD well controlled before and during pregnancy lowers the risk of adverse outcomes for both parent and baby; understanding which medications are safe and which should be stopped is crucial for family planning.

People with IBD and other IMIDs often need ongoing medication during pregnancy.

Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Pregnancy and fertility. The original article is from hmpgloballearningnetwork.com.

Cure8 found this source from Inflammatory bowel diseases, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Pregnancy and fertility. Open the original article for the full...

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...

This helps people with IBD and their care teams make delivery plans: if perianal disease is not active, having IBD alone was not linked to higher perineal injury risk in first-time vaginal births in this study.

People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.

People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...

An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...

Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...

High and rising out-of-pocket costs can force people with Crohn’s disease to worry about medical debt, skip care, or make major life changes. Policy choices about insurance coverage (like Medicaid expansion) can...

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...

People with UC who need biologic therapy during conception or pregnancy often face limited evidence about safety and effectiveness; this case suggests ustekinumab may be an option when other drugs fail or are stopped for...

An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...

Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...

The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK...

The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...

This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...

The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.